Akero Therapeutics, Inc. is a high-risk pharmaceutical company in the United States focusing on developing innovative treatments for metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). The company's ESG score is 31.7, indicating its commitment to environmental, sustainability, and governance practices. Akero Therapeutics is dedicated to addressing the unmet medical needs related to NASH with its product candidate efruxifermin, an FGF21 analog with promising potential.